

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: July 25, 2006 <i>(use as many sheets as necessary)</i>			Application Number	Unassigned 10/587184	
			Filing Date	01/13/2005	
			First Named Inventor	Pierre J-M RIVIERE	
			Group Art Unit	Unassigned	
			Examiner Name	Unassigned	
Sheet	1	of	1	Attorney Docket Number	052209-0150

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	A1	WO	01/21 198	A1	ELI LILLY & COMPANY	3/29/2001		
	A2	WO	02/28420	A2	Michael F. HOLICK	4/11/2002		
	A3	WO	96/22790		XENOTECH INCORPORATED	8/1/1996		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A4	Eric A.G. BLOMME et al., "Skeletal Metastasis of Prostate Adenocarcinoma in Rats: Morphometric Analysis and Role of Parathyroid Hormone-Related Protein", The Prostate 39:187-197 (1999).	
	A5	M. KUBOTA et al., "Efficacy and specificity of human parathyroid hormone analogues as antagonists in intact clonal osteogenic sarcoma cells", Journal of Endocrinology (1986) 108, 261-265.	
	A6	Theresa A. GUISE et al., "Evidence for a Causal Role of Parathyroid Hormone - related Protein in the Pathogenesis of Human Breast Cancer - mediated Osteolysis", J. Clin. Invest., Vol. 98, No. 7, October 1996, pp. 1544-1549.	
	A7	Shafaat A. RABBANI et al., "OVER-PRODUCTION OF PARATHYROID HORMONE-RELATED PEPTIDE RESULTS IN INCREASED OSTEOLYTIC SKELETAL METASTASIS BY PROSTATE CANCER CELLS IN VIVO", Int. J. Cancer: 80, 257-264 (1999).	
	A8	Manali BENDRE MD et al., "Breast Cancer Metastasis to Bone It is Not all About PTHrP", CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, Number 415S, pp. S39-S45 (2003).	

Examiner Signature

/Xiaozhen Xie/

Date Considered

08/12/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /X.Z./